Baird raised the firm’s price target on Bio-Techne to $73 from $68 and keeps an Outperform rating on the shares. The firm said though management noted signs of market stabilization in December/January, the company expects 3Q organic revenue to be similar toQ2. Baird thinks shares could remain pressured until there’s improved visibility around a return to growth, let alone double-digit growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TECH: